New spray chemotherapy trial targets Stomach-Lining cancer
NCT ID NCT07349043
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new way to deliver chemotherapy for colorectal cancer that has spread to the lining of the abdomen. Doctors use a spray (PIPAC) to send the drugs mitomycin or raltitrexed directly into the belly during a keyhole surgery. The main goal is to find a safe dose and check for side effects in 42 adults who are also getting standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mitomycin or raltitrexed delivered as a pressurized aerosol into the abdomen
What this could lead to
If this works, it could offer a new way to control colorectal cancer that has spread to the abdomen, potentially improving survival when combined with standard chemotherapy.
What could go wrong
This is a very early Phase 1 trial with only 42 people, focused on finding a safe dose, not proving it works. The treatment may cause side effects like nausea, fatigue, or pain, and it is unclear if it will actually help patients live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRC (COLORECTAL CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital, Zhejiang University School of Medicine 88 Jiefang Road Hangzhou, Zhejiang 310009, China
RECRUITINGHangzhou, Other (Non U.s.), 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••